ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0862

Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, clinical trial, immunology, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: SLE – Treatment Poster I

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus nephritis (AURORA 1), patients treated with VCS in combination with MMF, achieved renal response rates of 40.8% vs. 22.5% for the control arm (OR 2.65; p < 0.001). Drug-drug interactions have been demonstrated between CsA and MMF, where CsA interferes with MPA recirculation resulting in up to 50% lower exposure to mycophenolic acid (MPA), the active metabolite of MMF. While VCS did not demonstrate a negative impact on MPA levels in transplantation, the primary objective of this study was to investigate the effect of VCS on MPA levels in subjects with systemic lupus erythematosus (SLE), with or without lupus nephritis.

Methods: Twenty-five subjects with Systemic Lupus Erythematosus, treated with MMF at an oral dose of 1 g BID for at least 28 days prior to screening were enrolled and continued at the same dose throughout the study. Voclosporin was administered at a dose of 23.7 mg BID for seven consecutive days, starting in the evening of Day 1 and ending with the morning dose on Day 7.  Blood samples for PK analysis of MPA and mycophenolic acid glucuronide (MPAG) were were collected at pre-am. doses and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 6, 8, 10, and 12 hours post-a.m. doses after the morning dose of both drugs on Day 1 and 7. Analyses were performed using Phoenix™ WinNonlin® (Version 6.3)

Results: MPA exposure parameters were similar in the absence and presence of VCS (Cmax: 16.5 µg/mL [Day 1] vs. 15.8 µg/mL [Day 7], AUC0-12: 39.1 µg.h/mL [Day 1] vs. 40.8 µg.h/mL [Day 7]). The median time to Tmax was similar on both days, with comparable ranges of individual values. MPAG exposure showed a small increase in the presence of VCS (12% for Cmax and 27% for AUC0-12). Voclosporin exposure was consistent with previous studies. Administration of VCS with MMF over 7 days was well tolerated

Conclusion: There is no clinically meaningful interaction between voclosporin and MMF. As changes in exposure to MPA may affect its efficacy and safety, these data confirm that VCS and MMF can be given concomitantly without the need to adjust MMF dose


Disclosure: T. van Gelder, Vitaeris, 5, Aurinia Pharmaceuticals, 5, Astellas, 8; R. Huizinga, Aurinia Pharmaceuticals Inc., 1, 3; N. Solomons, Aurinia Pharmaceuticals, 1, 3; L. Lisk, Aurinia Pharmaceuticals, 1, 3.

To cite this abstract in AMA style:

van Gelder T, Huizinga R, Solomons N, Lisk L. Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/voclosporin-does-not-decrease-mycophenolic-acid-concentrations-in-patients-with-sle/. Accessed March 3, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/voclosporin-does-not-decrease-mycophenolic-acid-concentrations-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.